Stockreport

AD/PD 2025: Buntanetap shows promise in early Parkinson's with mild dementia [Yahoo! Finance]

Annovis Bio, Inc.  (ANVS) 
PDF six-month, randomised, double-blind, placebo-controlled Phase III clinical trial investigating the efficacy, safety, and tolerability of 10mg and 20mg doses of buntaneta [Read more]